Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Amortization of Deferred Charges: 2019-2021

Historic Amortization of Deferred Charges for Anika Therapeutics (ANIK) over the last 3 years, with Sep 2021 value amounting to $400,000.

  • Anika Therapeutics' Amortization of Deferred Charges fell 2.68% to $400,000 in Q3 2021 from the same period last year, while for Sep 2021 it was $1.7 million, marking a year-over-year increase of 18.95%. This contributed to the annual value of $1.5 million for FY2020, which is 29.86% up from last year.
  • According to the latest figures from Q3 2021, Anika Therapeutics' Amortization of Deferred Charges is $400,000, which was down 21.10% from $507,000 recorded in Q2 2021.
  • In the past 5 years, Anika Therapeutics' Amortization of Deferred Charges ranged from a high of $507,000 in Q2 2021 and a low of $289,000 during Q3 2019.
  • Moreover, its 3-year median value for Amortization of Deferred Charges was $385,000 (2020), whereas its average is $365,636.
  • Per our database at Business Quant, Anika Therapeutics' Amortization of Deferred Charges surged by 42.21% in 2020 and then decreased by 2.68% in 2021.
  • Anika Therapeutics' Amortization of Deferred Charges (Quarterly) stood at $299,000 in 2019, then surged by 32.11% to $395,000 in 2020, then dropped by 2.68% to $400,000 in 2021.
  • Its last three reported values are $400,000 in Q3 2021, $507,000 for Q2 2021, and $405,000 during Q1 2021.